Endo Pharmaceuticals Inc. and BioDelivery Sciences International, Inc announced that the U.S. FDA has approved BELBUCA™ (buprenorphine) buccal film for use in patients with chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.  Belbuca is the first and only analgesic buprenorphine developed with a dissolving film that is absorbed through the inner lining of the cheek for chronic pain management.  The drug is expected to be commercially available in the U.S. during the first quarter of 2016.  The availability of this new, convenient and flexible treatment option is important for patients whose lives are burdened by chronic pain, a debilitating condition that affects more Americans than diabetes, heart disease and cancer combined.